CC
PACB icon

Centiva Capital’s Pacific Biosciences PACB Stock Holding History

Centiva Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,400
Closed -$107K – 1563
2022
Q3 		$107K Buy
+18,400
New +$106K ﹤0.01% 1282

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centiva Capital's PACB Position: Q4 2024 in Review

Centiva Capital sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 23,358 shares — an estimated $39.7K sold.

Centiva Capital first reported a position in PACB in Q4 2019 and held it in 5 quarters. The position peaked at $414K in Q3 2022. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Centiva Capital reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 23,358 Pacific Biosciences shares in Q4 2024, an estimated $39.7K.
  • Centiva Capital first reported a position in Pacific Biosciences in Q4 2019 and held it in 5 quarters.
  • Centiva Capital's Pacific Biosciences position peaked at $414K in Q3 2022.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.